We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

8 hedge funds and large institutions have $16K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 6 → 8 (+2)

23% more capital invested

Capital invested by funds: $13K → $16K (+$3K)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AA
Ancora Advisors
Ohio
+$1K
2
CCB
Cutter & Co Brokerage
Missouri
+$252

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$7K – – –
LDB
2
Lee, Danner & Bass
Tennessee
$3K – – –
CAPTRUST Financial Advisors
3
CAPTRUST Financial Advisors
North Carolina
$2K – – –
CCB
4
Cutter & Co Brokerage
Missouri
$2K +$252 +3,750 +14%
ACM
5
Academy Capital Management
Texas
$1K – – –
AA
6
Ancora Advisors
Ohio
$1K +$1K +14,650 New

PVCT Hedge Fund Activity: Q1 2021 in Review

8 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2021, worth a combined $16K — up 23% from $13K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new PVCT positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Ancora Advisors, opening a new position worth an estimated $1K.

  • 8 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2021, up from 6 in Q4 2020.
  • Funds reported $16K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2021, up 23% quarter-over-quarter.
  • 2 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2021 and 0 closed out, a net change of +2 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q1 2021 was Ancora Advisors, an estimated $1K added.

Based on aggregated 13F filings for Q1 2021.